跳至主要內容

藥品參考

Dapagliflozin-saxagliptin

Dapagliflozin-saxagliptin is a medicine in the class gastrointestinal tract. It is used for diabetes mellitus.

最後更新

僅供醫療專業人員參考。本頁為簡要摘要,並非醫療建議,亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。

本頁的臨床內容僅提供英文版。

重點資訊

藥物類別
Gastrointestinal Tract
ATC 代碼
A10BD21
常見劑型
錠劑
常見規格
5 mg
商品名
3
國家與市場
3

劑型、規格與商品名稱會因國家而異。請核對您手上的產品。

用途

作用方式

Dapagliflozin: Selective sodium-glucose transporter-2 (SGLT2) inhibitor; SGLT-2, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen; SGLT2 inhibitors reduce glucose reabsorption and lower the renal threshold for glucose, thereby increasing urinary glucose excretion

成人常用劑量(仿單摘要)

Type 2 Diabetes Mellitus: 1 tablet (ie, 10mg/5mg) PO qDay in AM with or without food

僅摘錄仿單中第一行劑量說明;完整的劑量內容請見 App。

懷孕與哺乳

懷孕
Unsafe Dapagliflozin: kidney changes in rat offspring; not recommended in the 2nd and 3rd trimesters. Saxagliptin: limited data, no harm in animals. Stop the combination when pregnancy is detected; insulin is preferred.
哺乳
Unsafe No human milk data for either component; both pass into rat milk. Because of possible serious infant reactions (dapagliflozin and kidney maturation), the US label advises not to breastfeed.

已通報的副作用

  • Diarrhea
  • Back Pain
  • Upper respiratory tract infection (URI)
  • Urinary tract infections
  • Dyslipidemia
  • Headaches

禁忌症

  • History of hypersensitivity to dapagliflozin or saxagliptin, including anaphylaxis, angioedema, or exfoliative skin conditions
  • Moderate-to-severe renal impairment (eGFR <45 mL/min/1.73 m²), end-stage renal disease, or patients on dialysis

哪些人需要特別留意

  • Acute pancreatitis reported; after initiating drug, monitor for signs and symptoms of pancreatitis; if suspected, promptly discontinue dapagliflozin/saxagliptin and initiate appropriate management
  • May increase risk for developing heart failure (HF) or exacerbation of existing HR; observe patients for signs and symptoms of HF
  • Serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization reported in patients receiving SGLT2 inhibitors, including dapagliflozin; treatment with SGLT2 inhibitors increases risk for urinary tract infections; evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated

請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏,以及您正在使用的所有其他藥物或保健品。

Pro+ 會員專屬

解鎖完整頁面

建立帳號並開始 Pro+ 試用,即可開啟 Dapagliflozin-saxagliptin 的完整藥品專論:劑量、懷孕與哺乳、副作用、警示及所有交互作用。

  • Dosing by age, kidney and liver function, and further dose lines
  • Renal and hepatic dose adjustments
  • Paediatric dosing
  • How to give it
  • Pharmacokinetics
  • Patient counselling points
  • Food interactions

在網頁版免費試用 Pro+ 14 天,無需信用卡。

同類別的其他藥品

常見問題

What is Dapagliflozin-saxagliptin used for?

Dapagliflozin-saxagliptin is a medicine in the class gastrointestinal tract. It is used for Diabetes mellitus.

What side effects have been reported with Dapagliflozin-saxagliptin?

Diarrhea, Back Pain, Upper respiratory tract infection (URI), Urinary tract infections, Dyslipidemia, Headaches.

Can Dapagliflozin-saxagliptin be taken in pregnancy or while breastfeeding?

Pregnancy: Unsafe. Dapagliflozin: kidney changes in rat offspring; not recommended in the 2nd and 3rd trimesters. Saxagliptin: limited data, no harm in animals. Stop the combination when pregnancy is detected; insulin is preferred. Breastfeeding: Unsafe. No human milk data for either component; both pass into rat milk. Because of possible serious infant reactions (dapagliflozin and kidney maturation), the US label advises not to breastfeed.

What does Dapagliflozin-saxagliptin interact with?

MediHelp does not list a checked interaction for Dapagliflozin-saxagliptin yet. Always tell your pharmacist about every medicine you take.

在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查

在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用,並使用劑量工具。

依 A–Z 瀏覽 · 藥品參考

取得 App 登入